⌘K
t
Scancell Holdings plc announced the result of its Annual General Meeting held on 25 October 2024. All resolutions proposed at the meeting were duly passed.
| Date | 25 Oct 2024 |
| Time | 15:26:51 |
| Category | AGMs and other meetings |
| ID | 7406J |
25 October 2024
Scancell Holdings plc
("Scancell" or the "Company")
Result of Annual General Meeting
Scancell Holdings plc (AIM: SCLP), the developer of novel immunotherapies for the treatment of cancer, announces that all resolutions proposed at the Annual General Meeting held today were duly passed.
-ENDS-
|
For further information, please contact:
|
|
|
Scancell Holdings plc |
+44 (0) 20 3709 5700 |
|
Professor Lindy Durrant, CEO Dr Jean-Michel Cosséry, Non-Executive Chairman
|
|
|
Panmure Liberum Limited (Nominated Advisor and Joint Broker) |
+44 (0) 20 7886 2500 |
|
Emma Earl/ Freddy Crossley/ Will Goode/ Mark Rogers (Corporate Finance) |
|
|
Rupert Dearden (Corporate Broking)
|
|
|
WG Partners LLP (Joint Broker) |
+44 (0) 20 3705 9330 |
|
David Wilson/ Claes Spang/ Satheesh Nadarajah/ Erland Sternby
|
|
|
ICR Healthcare |
|
|
Mary-Jane Elliott/ Angela Gray/ Lindsey Neville |
+44 (0) 20 37095700
|
About Scancell
Scancell is a clinical stage immunotherapy company that is leveraging its proprietary research, built up over many years of studying the human adaptive immune system, to generate novel medicines to treat significant unmet needs in cancer. The Company is building a pipeline of innovative products by utilising its four technology platforms: Moditope® and ImmunoBody® for vaccines and GlyMab® and AvidiMab® for antibodies. Adaptive immune responses include antibodies and T cells (CD4 and CD8), both of which can recognise damaged or infected cells. In order to destroy such cancerous or infected cells, Scancell uses either vaccines to induce immune responses or monoclonal antibodies (mAbs) to redirect immune cells or drugs. The Company's approaches are that vaccines (ImmunoBody® and Moditope®) use unique receptors to target antigens to activated antigen presenting cells whereas its mAb portfolio targets glycans or sugars that are added onto proteins and / or lipids (GlyMab®) or enhances the potency of antibodies and their ability to directly kill tumour cells (AvidiMab®).
Scancell is headquartered in Oxford, United Kingdom and is listed on AIM (LSE.SCLP.L). For further information about Scancell, please visit: https://www.scancell.co.uk.